Tivic Health exercises licensing option for Entolimod

Tivic Health (TIVC) announced that it exercised its licensing option for the exclusive, worldwide rights to advance Entolimod for a second indication, Neutropenia. This expansion of commercial rights is part of the license agreement with Statera Biopharma for its late-stage Toll-like Receptor 5 immunotherapy program Entolimod. Under the terms of the company’s previously announced agreement with Statera Biopharma, Tivic secured a worldwide exclusive license for Entolimod as a potential treatment for acute radiation syndrome, or ARS. As previously announced, Tivic Health entered into a license agreement with Statera Biopharma, Inc. to acquire the exclusive worldwide license for the TLR5 agonist program Entolimod for ARS as well as the option to acquire the exclusive worldwide license for certain additional indications. Future payments under the agreement will be milestone-driven, ensuring alignment with the clinical and commercial success of the TLR5 program for the licensed indications. This structure allows Tivic to strategically manage investment while maximizing potential returns as the assets progress toward FDA approval and commercialization.